Further experience with antihuman lymphocyte globulin (Behring): no effect on cadaveric renal graft survival.
In 1977 we reported that 1 year cadaveric renal graft survival was improved in patients treated with high dose anti-human lymphocyte globulin (AHLG) (Behring). Such a beneficial effect of this agent was not confirmed in the present study with an enlarged series of patients and with a longer follow-up time. Nor was there any gain in respect of renal function or any steroid sparing effect. The only indication of an immunosuppressive effect is that the rejection episodes possibly occurred later in the patients given the high dose AHLG.
D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D002102:Cadaver; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged
D000961:Antilymphocyte Serum